Noble Pharma

Executive Summary

Noble Pharma is a U.S.-based contract development and manufacturing organization (CDMO) specializing in small molecule drug development and manufacturing. Founded in 2018 and headquartered in New York with a 50,000-square-foot facility in Menomonie, Wisconsin, the company offers end-to-end services from lab-scale development to commercial production. Its experienced team caters to pharmaceutical clients requiring scalable, high-quality manufacturing solutions. As a private entity, Noble Pharma operates in the competitive CDMO space, leveraging its mid-sized facility to provide flexible and responsive service. The CDMO market continues to expand due to increasing pharmaceutical outsourcing, and Noble Pharma is well-positioned to capture demand from emerging biotechs and established pharma companies seeking reliable partners. Its focus on small molecules and drug delivery differentiates it within a fragmented landscape. While the company does not disclose financials, its growth trajectory appears steady. Key risk factors include limited scale compared to larger CDMOs and reliance on a single facility. However, its agility and expertise in early-to-commercial manufacturing provide a niche advantage. Expansion and strategic partnerships remain critical to scaling operations.

Upcoming Catalysts (preview)

• 2027Facility Capacity Expansion60% success
• Q3 2026New Major Client Contract Win50% success
• TBDLaunch of Novel Drug Delivery Platform40% success